Showing results (1-10 of 265) with videos related to
Sort By:
Pageof 27
Annals of Internal Medicine|March 10, 2020
Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness AnalysisRochelle P Walensky, Tim Horn, Nicole C McCann, et al.Current HIV/AIDS Reports|June 26, 2013
Combination HIV prevention: the value and interpretation of mathematical modelsRochelle P WalenskyTopics in HIV Medicine : a Publication of the International AIDS Society, USA|November 6, 2009
Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policyRochelle P WalenskyLancet (London, England)|February 22, 2021
Insurance coverage and financing landscape for HIV treatment and prevention in the USAJennifer Kates, Lindsey Dawson, Tim H Horn, et al.Annals of Emergency Medicine|June 21, 2011
Cost-effectiveness analysis and HIV screening: the emergency medicine perspectiveHeather Hsu, Rochelle P WalenskyThe Journal of Infectious Diseases|March 20, 2019
The Costs of Drugs in Infectious Diseases: Branded, Generics, and Why We Should CareSydney Costantini, Rochelle P WalenskyAnnals of Internal Medicine|September 20, 2006
Rapid HIV testing at home: does it solve a problem or create one?Rochelle P Walensky, A David PaltielCurrent Infectious Disease Reports|January 27, 2007
Testing for HIV infection in the United StatesLindsey L Wolf, Rochelle P WalenskyClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2009
The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essentialRochelle P Walensky, Daniel R KuritzkesClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 26, 2014
Focusing National Institutes of Health HIV/AIDS research for maximum population impactRochelle P Walensky, Judith D Auerbach, Pageof 27